Volatile Movements: Visa Inc (NYSE:V), OpGen Inc (NASDAQ:OPGN)
Trading the news is a technique to trade equities, currencies and other financial instruments on the financial markets. Trading news releases can be a noteworthy tool for financial shareholders. Economic news reports often drive strong short-term moves in the markets, which may create trading opportunities for traders. Declarations about corporate profits, a change in administration, rumors of a merger, are events that can cause a company’s share price to move wildly up or down. Interest rates, unemployment and export rates, or the central bank’s policy shifts, can cause a deep change of an exchange rate.
Shares of Visa Inc (NYSE:V) gained 1.84% to $99.92 on Friday. The stock is currently trading at $99.92 per share, floating in a range of $99.09 to $100.49. The stock is moving on high volume, traded at a volume of 9.82 million shares, as compared to its average daily volume of 8.19 million shares. Trading volume, or volume, is the number of shares or contracts that point towards the overall activity of a security or market for a given period. Trading volume is a key technical indicator an investor uses to identify momentum in a stock and confirm a trend or trend reversal. Volume gives an investor an idea of the price action of a security and whether he should buy or sell the security.
Trading volume can also signal when an investor should take profits and sell a security because of low activity. If there is no relationship between the trading volume and the price of a security, this signals weakness in the current trend and a possible reversal. The market capitalization billion for the company is reported at $230.05 Billion.
OpGen Inc (NASDAQ:OPGN) opened at $0.41. It reached an intraday trading high of $0.42 and now trading at $0.357. The stock price declined -0.023 points or -5.95% at the market. The total volume traded for the day is 8.55 million, as compared to its average daily volume of 1.65 million shares. The current EPS for the company has been recorded at $-1.00 and the beta value recorded by the company stands at 0.00 points.
On July 19, a precision medicine company using molecular diagnostics and informatics to combat infectious disease declares the closing of its formerly declared public offering of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of about $10 million. The Company intends to use the net proceeds of this offering for general corporate purposes, counting working capital and product development, particularly development of its rapid antibiotic resistance diagnostic product, and repayment of all outstanding bridge financing notes.
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering.
“We are happy this public offering involving new and existing shareholders, in addition to members of administration, has been accomplished and look forward to advancing our business strategy,” said Evan Jones, chairman and chief executive officer of OpGen.
Each unit includes one share of common stock and one warrant to purchase one share of common stock at an exercise price of $0.425 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one warrant to purchase one share of common stock at an exercise price of $0.425 per share. The common warrants are exercisable right away have a five-year term from the date of issuance.